PARP1 and cancer: For example, talazoparib is 100-fold more potent at trapping PARP1 on DNA and >50 fold more potent at killing cancer cells than rucaparib and olaparib, although the apparent IC-50’s for all three compounds are quite similar (1–5 nM) (Shen et al., 2015).